Dr. Martens Future Growth

Future criteria checks 1/6

Dr. Martens is forecast to grow earnings and revenue by 5.9% and 3% per annum respectively. EPS is expected to grow by 6.4% per annum. Return on equity is forecast to be 16.4% in 3 years.

Key information

5.9%

Earnings growth rate

6.4%

EPS growth rate

Luxury earnings growth	10.9%
Revenue growth rate	3.0%
Future return on equity	16.4%
Analyst coverage	Good
Last updated	27 Sep 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

DB:3U2 - Analysts future estimates and past financials data (GBP Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	946	74	93	197	6
3/31/2026	885	56	84	162	7
3/31/2025	829	28	77	148	7
3/31/2024	877	69	140	168	N/A
12/31/2023	927	86	82	120	N/A
9/30/2023	978	103	28	77	N/A
6/30/2023	989	116	27	77	N/A
3/31/2023	1,000	129	21	73	N/A
12/31/2022	979	153	62	105	N/A
9/30/2022	957	177	104	138	N/A
6/30/2022	933	179	132	161	N/A
3/31/2022	908	181	159	184	N/A
12/31/2021	867	118	129	151	N/A
9/30/2021	825	54	98	117	N/A
6/30/2021	799	44	120	138	N/A
3/31/2021	773	35	142	159	N/A
12/31/2020	747	61	156	175	N/A
9/30/2020	722	87	169	190	N/A
6/30/2020	697	81	134	156	N/A
3/31/2020	672	75	100	121	N/A
3/31/2019	454	17	39	56	N/A
3/31/2018	349	-6	30	46	N/A
3/31/2017	291	-11	N/A	34	N/A
3/31/2016	232	-12	N/A	26	N/A
3/31/2015	235	0	N/A	20	N/A
3/31/2014	164	-32	N/A	5	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 3U2's forecast earnings growth (5.9% per year) is above the savings rate (0.8%).

Earnings vs Market: 3U2's earnings (5.9% per year) are forecast to grow slower than the German market (20% per year).

High Growth Earnings: 3U2's earnings are forecast to grow, but not significantly.

Revenue vs Market: 3U2's revenue (3% per year) is forecast to grow slower than the German market (5.5% per year).

High Growth Revenue: 3U2's revenue (3% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: 3U2's Return on Equity is forecast to be low in 3 years time (16.4%).

Dr. Martens Future Growth

Future criteria checks 1/6

Key information

Recent future growth updates

Dr. Martens plc Provides Revenue Guidance for Fiscal Year 2023

Dr. Martens plc Provides Earnings Guidance for the Year 2022

Dr. Martens plc Provides Revenue Guidance for the Full Year 2023

Recent updates

Dr. Martens plc, Annual General Meeting, Jul 11, 2024

Dr. Martens plc Announces Executive Changes

Full year 2024 earnings released: EPS: UK£0.07 (vs UK£0.13 in FY 2023)

Dr. Martens plc Proposes Final Dividend for Fiscal Year Ended 31 March 2024, Payable on 1 October 2024

Marathon Partners Urges Dr. Martens to Buy Back Stock

Investor sentiment improves as stock rises 20%

Dr. Martens plc Announces CEO Changes

Dr. Martens plc Announces CEO Changes

Now 25% undervalued

Investor sentiment improves as stock rises 15%

Marathon Partners Calls for Strategic Review Process for Dr. Martens

Giles Wilson to Join Dr. Martens plc as CFO on May 27, 2024

New major risk - Revenue and earnings growth

Upcoming dividend of UK£0.016 per share at 6.5% yield

First half 2024 earnings released: EPS: UK£0.019 (vs UK£0.045 in 1H 2023)

Investor sentiment deteriorates as stock falls 17%

Now 36% undervalued after recent price drop

Dr. Martens plc Approves Interim Dividend, Payable on 2 February 2024

Dr. Martens plc Announces Management Changes

Dr. Martens plc to Report Fiscal Year 2024 Results on May 30, 2024

New major risk - Revenue and earnings growth

Now 21% undervalued

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 23%

CEO & Director recently bought €467k worth of stock

Investor sentiment improves as stock rises 18%

Now 27% undervalued after recent price drop

Full year 2023 earnings released: EPS: UK£0.13 (vs UK£0.18 in FY 2022)

Investor sentiment deteriorates as stock falls 15%

Dr. Martens plc to Report First Half, 2024 Results on Nov 30, 2023

Investor sentiment improves as stock rises 17%

Investor sentiment improves as stock rises 21%

Investor sentiment deteriorated over the past week

Dr. Martens plc Provides Revenue Guidance for Fiscal Year 2023

Now 21% undervalued after recent price drop

Upcoming dividend of UK£0.016 per share

Investor sentiment deteriorated over the past week

First half 2023 earnings released: EPS: UK£0.045 (vs UK£0.049 in 1H 2022)

Dr. Martens plc Provides Earnings Guidance for the Year 2022

High number of new directors

Investor sentiment improved over the past week

Dr. Martens plc to Report Fiscal Year 2023 Results on Jun 01, 2023

Full year 2022 earnings released: EPS: UK£0.18 (vs UK£0.036 in FY 2021)

Dr. Martens plc Provides Revenue Guidance for the Full Year 2023

Dr. Martens plc to Report First Half, 2023 Results on Nov 24, 2022

High number of new directors

Investor sentiment deteriorated over the past week

Independent Non-Executive Director recently bought €54k worth of stock

Investor sentiment deteriorated over the past week

Now 22% undervalued after recent price drop

Investor sentiment deteriorated over the past week

An unknown buyer acquired 6.5% stake in Dr. Martens plc (LSE:DOCS) from Ingrelux S.ÀR.L.

First half 2022 earnings: EPS in line with analyst expectations despite revenue beat

High number of new directors

Independent Non-Executive Director recently bought €97k worth of stock

Full year 2021 earnings released: EPS UK£0.036 (vs UK£7.48 in FY 2020)

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies